Аурорикс

General characteristics. Structure:

Active agent: moklobemida of 150 or 300 mg.

Pharmacological properties:

Pharmacological action - psychogogic, antidepressive.
Reversibly inhibits MAO A, slows down metabolism of noradrenaline, dopamine, serotonin that leads to increase in extracellular concentration of these neurotransmitters.

Pharmacodynamics. Improves mood and psychomotor activity; weakens depression symptoms — a dysphoria, nervous exhaustion, block, inability to concentrate attention; stops symptoms of sotsiofobiya.

Indications to use:

Depressive syndromes, sociophobia.

Route of administration and doses:

Inside, after food. Depressions: on 300–600 mg for 2–3 receptions, an initial daily dose — 300 mg, at heavy depressions can be increased to 600 mg. Increase in a dose is made not earlier than in 1 week after an initiation of treatment. When obtaining clinical effect the dose is reduced.

Sociophobia: on 600 mg a day in 2 receptions; an initial dose — 300 mg a day, about 4 days increase a dose to 600 mg a day. Reception on 300 mg a day more than 3 days is not recommended.

Features of use:

To patients at whom excitement or agitation are the main clinical manifestation of a boyolezna, Auroriks either do not appoint, or appoint in a combination with sedative (for example, drug from group of benzodiazepines). It is necessary to observe carefully patients with suicide tendencies, patients with schizophrenic symptoms or schizoaffective disorders, patients with a thyrotoxicosis or feokhromatsiotomy. It is necessary to avoid combined use of a moklobemid with klomipraminy or dextromethorphan. At pregnant women and nursing mothers it is necessary to correlate advantage of treatment to possible risk for a fruit and the child.

Side effects:

Frustration of a dream, agitation, alarm, irritability, dizziness, headache, paresthesias, visual disturbance, dryness in a mouth, gastrointestinal disturbances, skin reactions, signs of confusion of consciousness (quickly disappear after drug withdrawal).

Interaction with other medicines:

Strengthens and extends effect of sympathomimetics and, perhaps, opiates. Increases probability of development of side reactions from TsNS at a combination to pethidine, klomipraminy, dextromethorphan. Cimetidinum slows down biotransformation.

Contraindications:

Hypersensitivity, acute disorder of consciousness, children's age, concomitant use of a selegilin.

Use at pregnancy and feeding by a breast
Contraindicated.

Overdose:

Now there are few data on drug overdose. Agitation, the increased aggression and disturbances of the relations with surrounding people were observed.

Overdose treatment symptomatic.

Storage conditions:

In the dry, protected from light place, at a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

1 tablet, coated, contains a moklobemid of 150 or 300 mg; in the blister of 10 pieces, in a box 3 blisters.